The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain
With the emergence of knowledge implicating the human gut microbiome in the development and regulation of several physiological systems, evidence has accumulated to suggest a role for the gut microbiome in psychiatric conditions and drug response. A complex relationship between the enteric nervous system, the gut microbiota and the central nervous system has been described which allows for the microbiota to influence and respond to a variety of behaviors and psychiatric conditions. Additionally, the use of pharmaceuticals may interact with and alter the microbiota to potentially contribute to adverse effects of the drug. The gut microbiota has been described in several psychiatric disorders including depression and anxiety, but only a few reports have discussed the role of the microbiome in schizophrenia. The following review examines the evidence surrounding the gut microbiota in behavior and psychiatric illness, the role of the microbiota in schizophrenia and the potential for antipsychotics to alter the gut microbiota and promote adverse metabolic events.
KeywordsGut microbiome Gut brain axis Schizophrenia Antipsychotic-induced weight gain
DJM is supported by the Canadian Institutes of Health Research (CIHR Operating Grant MOP 142192), and the Centre for Addiction and Mental Health (CAMH) Foundation (Joanne Murphy Professorship). DJM and MKH are supported by a Generation Capital Award in collaboration with the Farncombe Family Digestive Health Research Institute and the CAMH Foundation. We thank Thomas Lee for assisting in the preparation of Fig. 1.
Compliance with ethical standards
Conflict of interest
These authors declare that they have no conflict of interest.
- 1.Dinan TG, Cryan JF (2016) Microbes, immunity and behavior: psychoneuroimmunology meets the microbiome. Neuropsychopharm. [Epub ahead of print]Google Scholar
- 2.Ipci K, Altintoprak N, Muluk NB, Senturk M, Cingi C (2016) The possible mechanisms of the human microbiome in allergic diseases. Eur Arch Oto-rhino-l. [Epub ahead of print]Google Scholar
- 8.Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, Codelli JA, Chow JC, Reisman SE, Petrosino JF, Patterson PH, Mazmanian SK (2013) Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155(7):1451–1463CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Castro-Nallar E, Bendall ML, Perez-Losada M, Sabuncyan S, Severance EG, Dickerson FB, Schroeder JR, Yolken RH, Crandall KA (2015) Composition, taxonomy and functional diversity of oropharynx microbiome in individuals with schizophrenia and controls. PeerJ 3:e1140CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Dinan TG, Cryan JF (2017) Gut-brain axis in 2016: brain-gut-microbiota axis mood, metabolism and behavior. Nat Rev Gastroenterol Hepatol. [Epub ahead of print]Google Scholar
- 19.Bercik P, Denou E, Collins J (2011) The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 141Google Scholar
- 32.Dickerson FB, Stallings C, Origoni A, Katsafanas E, Savage CL, Schweinfurth LA, Goga J, Khushalani S, Yolken RH (2014) Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. Prim Care Companion CNS Disord. doi: 10.4088/PCC.13m01579 PubMedPubMedCentralGoogle Scholar
- 42.Hahn MK, Wolever TM, Arenovich T, Teo C, Giacca A, Powell V, Clarke L, Fletcher P, Cohn T, McIntyre RS, Gomes S, Chintoh A, Remington GJ (2013) Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. J Clin Psychopharmaco 33(6):740–746CrossRefGoogle Scholar
- 43.Vidarsdottir S, de Leewu van Weenen JE, Frolich M, Roelfsema F, Romjin JA, Pijl H (2009) Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab 95(1):118–125Google Scholar
- 45.Kasai C, Sugimoto K, Moritani I, Tanaka J, Oya Y, Inoue H, Tameda M, Shiraki K, Ito M, Takei Y, Takase K (2015) Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing. BMC Gastroenterol 15:100CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Davey JK, O’Mahoney SM, Schellekens H, O’Sullivan O, Bienenstock J, Cotter PD, Dinan TG, Cryan JF (2012) Gender-dependent consequences of chronic olanzapine in the rat: effect on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology 221(1):155–169CrossRefPubMedGoogle Scholar
- 52.Bahr SM, Tyler BC, Wooldridge N, Butcher BD, Burns TL, Teesch LM, Oltman CL, Azcarate Peril MA, Kirby JR, Calarge CA (2015) Use of the second-generation antipsychotic, risperidone, and secondary weight change are associated with an altered gut microbiota in children. Transl Psychiatry 5:e652CrossRefPubMedPubMedCentralGoogle Scholar